Aurobindo's generic drug for osteoporosis approved by US FDA

Published: 9-Dec-2015
Media Regulatory

The global osteoporosis drugs market is seeing significant growth due to a rising geriatric population and changing lifestyles


India's Aurobindo Pharma has received final approval from the US FDA to manufacture and market the generic version of Risedronate Sodium tablets, used in the treatment of osteoporosis, in the American market.

The approval is an extension of a tentative nod received by the company on 10 October 2012.

Aurobindo's product is therapeutically equivalent to Warner Chilcott's Actonel tablets, which are also used in the treatment of osteoporosis.

The approved product had an estimated market size of US$113m for the 12 months ending October 2015, according to IMS data.

The osteoporosis drugs market is anticipated to grow from an estimated $11.23bn in 2015 to $14.8bn by 2022 at a CAGR of 4.0% during the forecast period.

The global osteoporosis drugs market is seeing significant growth due to a rising geriatric population and changing lifestyles impinging on bone health. Increasingly, the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are driving the growth of the market.

While North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of treatment, Asia-Pacific is the fastest growing region in terms of revenue.

  • Companies:
  • Aurobindo
See more

You may also like

Regulatory

Nearly 90,000 Gabapentin capsules are recalled by Aurobindo Pharma and Actavis

Read more
The capsules were manufactured at two plants in India

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Momentum in the US cannabidiol market gains retailers' attention Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
  4. Ametek Mocon achieves accreditation for analytical testing laboratory Ametek Mocon, provider of instruments and services for testing, measuring and analysing a variety of gases, has achieved ISO/IEC 17025 accreditation for its Minneapolis analytical testing laboratory
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Nearly 90,000 Gabapentin capsules are recalled by Aurobindo Pharma and Actavis

The capsules were manufactured at two plants in India
Ingredients

Indian API market on the up as domestic drug prices fall

Indian API manufacturers are branching out into new markets, while international suppliers could be hit by lower prices in the domestic market, writes Asia correspondent A Nair
Media

Pfizer signs generics deals with Indian firms

<p>Pfizer has signed agreements with two India-based pharmaceutical companies as it seeks growth in generics and emerging markets.</p>
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Subscribe now